Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

AI Briefing

• – Voyager Acquisition Corporation approved its business combination with Veraxa Biotech AG, with approximately 99.67% of Class A shares redeemed, leaving $885,556 in the trust account and 82,685 shares converting to the combined company.
• – The combined company will trade on Nasdaq under the new symbol VRXA after closing of the Business Combination.
• – Holders of the Company's Class A shares exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account.